Jennifer Schranz is senior vice president and global head of rare diseases in the R&D division at Ipsen.

On the podcast this week, she discusses a breakthrough treatment for primary biliary cholerangitis and cholestatic liver disease.

00:56-00:49: Background information
01:44-03:21: What are primary biliary cholerangitis (PBC) and cholestatic liver disease?
03:21-03:50: How rare is PBC?
03:50-04:45: How easy is PBC diagnosis?
04:45-05:45: What are the current treatments for the condition?
05:45-07:22: What are the challenges to innovation?
07:22-08:27: What is elafibranor?
08:27-08:37: How is it administered?
08:37-09:18: Is elafibranor taken for life?
09:18-11:08: What is the ELATIVE trial, and what were the results you presented at the AASLD Liver Meeting?
11:08-13:09: What was the reaction at the meeting?
13:09-13:55: A patient-centric approach
13:55-14:44: Is a cure for PBC a possibility?
14:44-17:20: How important are acquisitions to Ipsen’s pipeline?
17:20-18:33: Working on multiple diseases
18:33-19:58: How much impact can you have on liver diseases?
19:58-21:04: What are the next steps for elafibranor?

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! 

Stay updated by subscribing to our newsletter